Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 14,000 | |||
10 mg | 在庫あり | ¥ 18,500 | |||
25 mg | 在庫あり | ¥ 41,500 | |||
50 mg | 在庫あり | ¥ 74,500 | |||
100 mg | 在庫あり | ¥ 123,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 14,500 |
説明 | GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains. |
ターゲット&IC50 | BAZ2A:257 nM(Kd), BAZ2B:136 nM(Kd) |
In vitro | In U2OS cells transfected with mutant BAZ2A (N1873F), GSK2801 (1 μM) accelerates FRAP half-recovery time by displacing BAZ2A from chromatin. [1] |
In vivo | In male CD1 mice, GSK2801 (30 mg/kg, p.o. and i.p.) has reasonable in vivo exposure after oral dosing, modest clearance, and reasonable plasma stability. [1] |
分子量 | 371.45 |
分子式 | C20H21NO4S |
CAS No. | 1619994-68-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 18.6 mg/mL (50 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK2801 1619994-68-1 Apoptosis Chromatin/Epigenetic Epigenetic Reader Domain inhibit GSK 2801 Inhibitor TNBC BAZ2A GSK-2801 BAZ2B cetyl-lysine orally inhibitor